The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | ASCO lung cancer highlights

Name: ASCO lung cancer highlights
Uploaded: 2019-06-02T00:00:00Z
Duration: 1 min 30 s
Description: Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses some of the key lung cancer updates presented at ASCO 2019, specifically mentioning treatments targeting KRAS and the drug ramucirumab. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Roy Herbst • 2 Jun 2019

ASCO 2019

Lung Cancer Ramucirumab

REVEL

Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses some of the key lung cancer updates presented at ASCO 2019, specifically mentioning treatments targeting KRAS and the drug ramucirumab. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.